+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception

Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception

Clinica E Investigacion en Arteriosclerosis 26(6): 274-284

Atherogenic dyslipidemia is an important risk factor for cardiovascular disease. We aim to determine atherogenic dyslipidemia prevalence in primary care patients at moderate-very high cardiovascular risk and its associated cardiovascular risk perception in Spain. This cross-sectional study included 1137 primary care patients. Patients had previous cardiovascular disease, diabetes mellitus, SCORE risk ≥ 3, severe hypertension or dyslipidemia. Atherogenic dyslipidemia was defined as low HDL-C (<40 mg/dL [males], <50 mg/dL [females]) and elevated triglycerides (≥ 150 mg/dL). A visual analog scale was used to define a perceived cardiovascular disease risk score. Mean age was 63.9 ± 9.7 years (64.6% males). The mean BMI was 29.1 ± 4.3 kg/m(2), and mean waist circumference 104.2 ± 12.7 cm (males), and 97.2 ± 14.0 cm (females). 29.4% were smokers, 76.4% had hypertension, 48.0% were diabetics, 24.7% had previous myocardial infarction, and 17.8% peripheral arterial disease. European guidelines classified 83.6% at very high cardiovascular risk. Recommended HDL-C levels were achieved by 50.1% of patients and 37.3% had triglycerides in the reference range. Target LDL-C was achieved by 8.8%. The overall atherogenic dyslipidemia prevalence was 27.1% (34.1% in diabetics). This prevalence in patients achieving target LDL-C was 21.4%. Cardiovascular risk perceived by patients was 4.3/10, while primary care physicians scored 5.7/10. When LDL-C levels are controlled, atherogenic dyslipidemia is more prevalent in those patients at highest cardiovascular risk and with diabetes. This highlights the importance of intervention strategies to prevent the residual vascular risk in this population. Both patients and physicians underestimated cardiovascular risk.

(PDF emailed within 0-6 h: $19.90)

Accession: 055155568

Download citation: RISBibTeXText

PMID: 24931442

DOI: 10.1016/j.arteri.2014.04.002

Related references

Cardiovascular risk in patients with atherogenic dyslipidemia. Perspective of primary care physicians. Avanza study. Atherosclerosis 263: E281-E281, 2018

Prevalence of atherogenic dyslipidemia: association with risk factors and cardiovascular risk in Spanish working population. "ICARIA" study. Atherosclerosis 235(2): 562-569, 2015

Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. Journal of Dermatology 40(11): 923-926, 2015

Systematic Litertaure Review Of Direct Health Care Costs For Cardiovascular Events Among European Patients With Dyslipidemia Or High Cardiovascular Risk. Value in Health 18(7): A387-A387, 2015

Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. American Journal of Cardiology 100(10): 1511-1516, 2007

Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease. Current Medical Research and Opinion 21(7): 1091-1097, 2005

Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. Journal of Cardiovascular Pharmacology 57(2): 267-272, 2012

Smoking cessation and the risk of cardiovascular disease outcomes predicted from established risk scores: results of the Cardiovascular Risk Assessment among Smokers in Primary Care in Europe (CV-ASPIRE) study. Bmc Public Health 13: 362-362, 2013

Role of myocardial perfusion scintigraphy in predicting global cardiovascular risk and differentiating between patients with moderate and high cardiovascular risk. Nuclear Medicine Communications 37(8): 805-811, 2016

Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke 45(5): 1429-1436, 2014

Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease. Clinical Lipidology 6(3): 305-314, 2011

Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovascular Diabetology 7(): 31-31, 2008

Cardiovascular risk profile of patients with atherogenic dyslipidemia in middle age Lithuanian population. Lipids in Health and Disease 17(1): 208-208, 2018

Prevalence and knowledge of modifiable cardiovascular risk factors among patients of primary health care. Małopolska CArdiovascular Preventive Intervention Study (M-CAPRI). Przeglad Lekarski 73(9): 641-647, 2018

Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease. European Journal of Preventive Cardiology 23(12): 1289-1297, 2017